Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study

by Zacks Equity Research

Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.

The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck

by Zacks Equity Research

The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck

Christopher Vargas headshot

3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020

by Christopher Vargas

The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.

Tracey Ryniec headshot

Bull of the Day: InMode (INMD)

by Tracey Ryniec

What will you do to look good on Instagram?

Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy

by Zacks Equity Research

Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.

Sweta Killa headshot

Biotech ETFs Hit New Highs on Deal Activities

by Sweta Killa

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Allergan (AGN) Up 4.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AstraZeneca Sells Schizophrenia Drug Rights in US and Canada

by Zacks Equity Research

AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.

Ekta Bagri headshot

NASH Scorecard Year to Date: The Winners and the Losers

by Ekta Bagri

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Christopher Vargas headshot

3 Stocks for Value Investors to Buy as Market Reaches New High

by Christopher Vargas

The stock market closed at a record high today as the DJIA rose over 42 points and the S&P 500 gained 0.4%.

Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug

by Zacks Equity Research

Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.

Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex

by Zacks Equity Research

Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.

Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal

by Zacks Equity Research

Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.

The Zacks Analyst Blog Highlights: Booking, Allergan, Honda Motor, Infosys and Activision Blizzard

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Booking, Allergan, Honda Motor, Infosys and Activision Blizzard

Mark Vickery headshot

Top Stock Reports for Booking Holdings, Allergan & Honda Motor Co.

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Booking Holdings (BKNG), Allergan (AGN) and Honda Motor (HMC).

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase

by Zacks Equity Research

Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

by Kinjel Shah

Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.

Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed

by Zacks Equity Research

Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.

Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View

by Zacks Equity Research

Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.

Allergan (AGN) Q3 Earnings Meet Estimates

by Zacks Equity Research

Allergan (AGN) delivered earnings and revenue surprises of 0.00% and 4.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

by Zacks Equity Research

Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

Should You Buy Allergan (AGN) Ahead of Earnings?

by Zacks Equity Research

Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Allergan (AGN) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Allergan (AGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AbbVie (ABBV) Beats on Q3 Earnings & Sales, Tweaks EPS View

by Zacks Equity Research

AbbVie (ABBV) beats on both earnings and revenues in the third quarter. The company ups the lower end of its 2019 guidance for adjusted earnings per share.